ALKS Alkermes plc

Price (delayed)

$32.08

Market cap

$5.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.4

Enterprise value

$5.34B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
Alkermes's net income has soared by 50% YoY and by 34% from the previous quarter
The EPS has soared by 50% year-on-year and by 33% since the previous quarter
Alkermes's gross profit has decreased by 6% YoY but it has increased by 6% from the previous quarter
The revenue has grown by 5% from the previous quarter but it has contracted by 5% YoY
The debt has grown by 9% YoY
ALKS's quick ratio is down by 9% year-on-year

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
161.33M
Market cap
$5.18B
Enterprise value
$5.34B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.69
Price to sales (P/S)
4.69
EV/EBIT
N/A
EV/EBITDA
145.82
EV/Sales
4.86
Earnings
Revenue
$1.1B
EBIT
-$42.4M
EBITDA
$36.63M
Free cash flow
$89.89M
Per share
EPS
-$0.4
Free cash flow per share
$0.56
Book value per share
$6.84
Revenue per share
$6.84
TBVPS
$10.89
Balance sheet
Total assets
$1.94B
Total liabilities
$839.67M
Debt
$424.58M
Equity
$1.1B
Working capital
$654.32M
Liquidity
Debt to equity
0.39
Current ratio
2.71
Quick ratio
2.18
Net debt/EBITDA
4.54
Margins
EBITDA margin
3.3%
Gross margin
83.6%
Net margin
-5.7%
Operating margin
-4.9%
Efficiency
Return on assets
-3.3%
Return on equity
-5.8%
Return on invested capital
-2.9%
Return on capital employed
-2.7%
Return on sales
-3.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
0%
1 week
8.31%
1 month
3.12%
1 year
91.64%
YTD
60.8%
QTD
30.83%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.1B
Gross profit
$919.96M
Operating income
-$53.41M
Net income
-$62.83M
Gross margin
83.6%
Net margin
-5.7%
Alkermes's operating income has soared by 60% YoY and by 42% from the previous quarter
The company's operating margin has surged by 58% YoY and by 44% QoQ
Alkermes's net income has soared by 50% YoY and by 34% from the previous quarter
The net margin has grown by 48% YoY and by 37% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
4.69
P/S
4.69
EV/EBIT
N/A
EV/EBITDA
145.82
EV/Sales
4.86
The EPS has soared by 50% year-on-year and by 33% since the previous quarter
The P/B is 56% higher than the last 4 quarters average of 3.0 but 2.3% lower than the 5-year quarterly average of 4.8
The company's equity rose by 4.4% QoQ and by 3.4% YoY
ALKS's P/S is 62% above its last 4 quarters average of 2.9 but 22% below its 5-year quarterly average of 6.0
The revenue has grown by 5% from the previous quarter but it has contracted by 5% YoY

Efficiency

How efficient is Alkermes business performance
The ROIC has soared by 62% YoY and by 42% from the previous quarter
The ROS has soared by 56% year-on-year and by 45% since the previous quarter
The ROA has soared by 53% YoY and by 34% QoQ
The return on equity has surged by 51% year-on-year and by 35% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 131% higher than its total liabilities
The company's total liabilities rose by 13% YoY
ALKS's quick ratio is down by 9% year-on-year
The debt is 61% less than the equity
The debt has grown by 9% YoY
The debt to equity is up by 5% YoY but it is down by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.